Eli Lilly and Company (NYSE:LLY) Shares Purchased by Demars Financial Group LLC

Demars Financial Group LLC increased its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 77,111.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 518,864 shares of the company's stock after acquiring an additional 518,192 shares during the quarter. Eli Lilly and Company comprises approximately 1.2% of Demars Financial Group LLC's holdings, making the stock its 14th biggest position. Demars Financial Group LLC owned about 0.05% of Eli Lilly and Company worth $400,563,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Greenwood Gearhart Inc. raised its position in shares of Eli Lilly and Company by 9.4% during the fourth quarter. Greenwood Gearhart Inc. now owns 863 shares of the company's stock valued at $666,000 after buying an additional 74 shares during the last quarter. MSH Capital Advisors LLC bought a new stake in Eli Lilly and Company during the fourth quarter worth approximately $1,077,000. Everest Management Corp. bought a new stake in Eli Lilly and Company in the fourth quarter worth $292,000. Resurgent Financial Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 15.9% in the 4th quarter. Resurgent Financial Advisors LLC now owns 698 shares of the company's stock worth $539,000 after acquiring an additional 96 shares during the last quarter. Finally, Lifelong Wealth Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $849,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. Guggenheim lowered their target price on shares of Eli Lilly and Company from $973.00 to $928.00 and set a "buy" rating for the company in a research note on Monday. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $892.00 to $888.00 in a research report on Tuesday, April 8th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. StockNews.com upgraded Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Morgan Stanley lowered their target price on shares of Eli Lilly and Company from $1,146.00 to $1,124.00 and set an "overweight" rating for the company in a research note on Wednesday, April 9th. Two equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,012.00.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded up $106.80 during trading hours on Friday, hitting $841.70. The stock had a trading volume of 10,843,294 shares, compared to its average volume of 3,427,703. The firm has a 50-day moving average price of $829.09 and a 200 day moving average price of $820.35. The firm has a market capitalization of $798.08 billion, a price-to-earnings ratio of 71.88, a PEG ratio of 1.40 and a beta of 0.51. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.